Highlights

  • Supernus will release third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.
  • Management will host a call and webcast at 4:30 p.m. ET, with a replay on the investor relations site.
  • Its neuroscience portfolio includes approved treatments for ADHD, Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea.
  • The October 19 filing contains no financial results, guidance or balance sheet data, so none are reported here.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) shares were trading near their 52-week low at USD 41.21 on October 21, 2026, down 0.05%. The biopharmaceutical company announced on October 19 that it will report third quarter 2026 results on October 29 and host a conference call the same afternoon.

Based in Rockville, Maryland, Supernus is a Delaware corporation whose common stock is registered on The Nasdaq Stock Market. It describes itself as a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder, dyskinesia in Parkinson's disease patients receiving levodopa-based therapy, hypomobility in Parkinson's disease, postpartum depression, epilepsy, migraine, cervical dystonia and chronic sialorrhea. The company says it is developing a broad range of novel product candidates for CNS disorders.

What the Latest Filing Covers

The only document reviewed is a Form 8-K dated October 19, 2026, furnishing a short press release under Item 2.02. It is a scheduling notice rather than an earnings report. Jack Khattar, president and chief executive officer, and Tim Dec, senior vice president and chief financial officer, will host the call at 4:30 p.m. ET on Thursday, October 29. A live webcast will be available in the events and presentations section of the company's investor relations website, and participants can register in advance to receive dial-in details. A replay will be posted afterward, and the company says the webcast will remain available for 60 days.

What Is Not Disclosed

The filing does not include revenue, net income or loss, cash, debt, product sales, clinical or regulatory updates, or guidance. It therefore does not describe the company's current financial position, any material negative developments, or any recent positive ones. Its forward-looking statements section lists general risks, including the company's ability to sustain and increase profitability, raise sufficient capital, increase prescriptions and net revenue from its products and those acquired through its acquisition of Sage, protect its intellectual property, and obtain regulatory approvals for product candidates. It also cites changes in laws and regulations, macroeconomic conditions, trade disputes and tariffs. The filing gives no dates or details on the Sage acquisition.

Upcoming Milestone

The next scheduled event is the third quarter 2026 report on October 29, after which management will take questions following its prepared remarks. Figures on results, guidance and the balance sheet are not part of the material reviewed here.